logo
logo
BioLife Solutions, Inc.

BioLife Solutions, Inc.

NASDAQ•BLFS
CEO: Mr. Roderick de Greef
セクター: Healthcare
業種: Medical - Instruments & Supplies
上場日: 1989-11-22
BioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line that comprises of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides cryogenic freezer technology for controlled rate freezing and cryogenic storage of biologic materials; ultra-low temperature mechanical freezers; evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage and transport services. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.
連絡先情報
3303 Monte Villa Parkway, Suite 310, Bothell, WA, 98021, United States
425-402-1400
www.biolifesolutions.com
時価総額
$1.08B
PER (TTM)
-334.2
67
配当利回り
--
52週高値
$29.62
52週安値
$19.10
52週レンジ
31%
順位62Top 92.6%
1.9
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
弱い • 1.9 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025

財務ダッシュボード

Q3 2025 データ

売上高

$28.07M-8.19%
直近4四半期の推移

EPS

$0.01-127.10%
直近4四半期の推移

フリーCF

$2.80M-24.02%
直近4四半期の推移

2025 Q3 決算ハイライト

主なハイライト

Revenue Growth Strong Nine months revenue reached $77.43M, marking a 30% increase driven by product sales.
Operating Cash Flow Improved Net cash provided by operating activities was $15.20M for nine months, up from $6.79M prior.
Equity Position Strengthened Total shareholders' equity grew to $353.74M as of September 30, 2025, up from year-end 2024.
PanTHERA Acquisition Expensed Immediate $15.5M IPR&D expense recognized following the April 2025 PanTHERA asset acquisition.

リスク要因

Operating Loss Widened Nine months operating loss deteriorated to $(17.95M) compared to $(5.02M) in the prior period.
Deferred Tax Asset Risk Management projects a full $56.8M valuation allowance against U.S. deferred tax assets due to uncertainty.
Contingency Loss Recorded Recorded $1.4M loss contingency related to customer claims from the discontinued Global Cooling business.
Term Loan Maturity Near Remaining Term Loan principal of $7.50M matures in June 2026, requiring future financing action.

見通し

SAVSU Divestiture Completed SAVSU Transaction closed October 6, 2025, for $25.5M; accounting for divestiture is not yet finalized.
Sufficient Liquidity Expected Current cash levels are believed sufficient to meet liquidity needs for at least the next twelve months.
R&D Investment Increased Research and development expenses rose 27% for nine months, driven by increased personnel costs.
Stock Comp Costs Remaining $0.9M unrecognized non-cash compensation cost remains for performance-based awards vesting over 0.2 years.

同業比較

売上高 (TTM)

STAAR Surgical CompanySTAA
$94.91B
+30136.8%
Neogen CorporationNEOG
$880.32M
-3.7%
NovoCure LimitedNVCR
$642.27M
+11.2%

粗利益率 (最新四半期)

Xeris Biopharma Holdings, Inc.XERS
85.2%
+10.3pp
STAAR Surgical CompanySTAA
82.2%
+17.6pp
Harrow, Inc.HROW
75.3%
-0.3pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
NEOG$2.39B-4.0-26.9%23.6%
ESTA$2.16B-26.5-253.8%77.1%
HROW$1.87B-376.4-9.0%69.4%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
N/M
売上高の変動が大きい
4四半期純利益CAGR
-63.2%
収益性の低下
キャッシュフロー安定性
100%
優れたキャッシュフローの実績

深度リサーチ

次回決算:2026年3月2日
|
EPS:-$0.02
|
売上高:-
財務レポート
財務データ
ニュース
全年度
  • Form 10-Q - Q3 2025

    会計期末: 2025年9月30日|提出日: 2025年11月6日|
    売上高: $28.07M-8.2%
    |
    EPS: $0.01-127.1%
    予想を上回る
  • Form 10-Q - Q2 2025

    会計期末: 2025年6月30日|提出日: 2025年8月7日|
    売上高: $25.42M+28.9%
    |
    EPS: $-0.33-26.7%
    予想を下回る
  • Form 10-Q - Q1 2025

    会計期末: 2025年3月31日|提出日: 2025年5月8日|
    売上高: $23.94M+29.9%
    |
    EPS: $-0.01-95.7%
    予想を上回る
  • Form 10-K/A - FY 2024

    会計期末: 2024年12月31日|提出日: 2025年4月8日|
    売上高: $82.25M-42.6%
    |
    EPS: $-0.44+71.1%
    予想を下回る
  • Form 10-K - FY 2024

    会計期末: 2024年12月31日|提出日: 2025年3月3日|修正版データを参照
  • Form 10-Q - Q3 2024

    会計期末: 2024年9月30日|提出日: 2024年11月12日|
    売上高: $30.57M+29.7%
    |
    EPS: $-0.04-94.5%
    予想を上回る
  • Form 10-Q - Q2 2024

    会計期末: 2024年6月30日|提出日: 2024年8月9日|
    売上高: $19.72M-50.1%
    |
    EPS: $-0.45+95.7%
    予想を下回る
  • Form 10-Q - Q1 2024

    会計期末: 2024年3月31日|提出日: 2024年5月10日|
    売上高: $18.43M-51.1%
    |
    EPS: $-0.22-31.3%
    予想通り